Evidence map›Paper›PMID 29618796›Full record

ArticleScientific reports2018

Prognostic value of cancer antigen -125 for lung adenocarcinoma patients with brain metastasis: A random survival forest prognostic model.

Hao Wang, Liuhai Shen, Jianhua Geng, Yitian Wu, Huan Xiao, Fan Zhang, Hongwei Si

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hao WangDepartment of Radiotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, 230022, China.
Liuhai ShenDepartment of Nuclear Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, 230022, China.
Jianhua GengDepartment of Nuclear Medicine, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Yitian WuDepartment of Nuclear Medicine, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Huan XiaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, 230022, China.
Fan ZhangDepartment of Radiotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, 230022, China.
Hongwei SiDepartment of Nuclear Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, 230022, China. sihw@163.com.ORCID 0000-0002-0703-8939
Anhui Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Using random survival forest, this study was intended to evaluate the prognostic value of serum markers for lung adenocarcinoma patients with brain metastasis (BM), and tried to integrate them into a prognostic model. During 2010 to 2015, the patients were retrieved from two medical centers. Besides the Cox proportional hazards regression, the random survival forest (RSF) were also used to develop prognostic model from the group A (n = 142). In RSF of the group A, the factors, whose minimal depth were greater than the depth threshold or had a negative variable importance (VIMP), were firstly excluded. Subsequently, C-index and Akaike information criterion (AIC) were used to guide us finding models with higher prognostic ability and lower overfitting possibility. These RSF models, together with the Cox, modified-RPA and lung-GPA index were validated and compared, especially in the group B (CAMS, n = 53). Our data indicated that the KSE125 model (KPS, smoking, EGFR-20 (exon 18, 19 and 21) and Ca125) was the best in survival prediction, and performed well in internal and external validation. In conclusions, for lung adenocarcinoma patients with brain metastasis, a validated prognostic nomogram (KPS, smoking, EGFR-20 and Ca125) can more accurately predict 1-year and 2-year survival of the patients.

Indexed as

Models, StatisticalAdenocarcinoma of LungAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBrain NeoplasmsCA-125 AntigenChemoradiotherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNomogramsPrognosisBiomarkers, TumorCA-125 Antigen

Identifiers

PMID29618796
PMCPMC5884842
OpenAlexW2805278979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.